Impulse Control Disorders in Parkinson Disease: a Cross-sectional Study of 3090 Patients
Overview
Authors
Affiliations
Context: An association between dopamine-replacement therapies and impulse control disorders (ICDs) in Parkinson disease (PD) has been suggested in preliminary studies.
Objectives: To ascertain point prevalence estimates of 4 ICDs in PD and examine their associations with dopamine-replacement therapies and other clinical characteristics.
Design: Cross-sectional study using an a priori established sampling procedure for subject recruitment and raters blinded to PD medication status.
Patients: Three thousand ninety patients with treated idiopathic PD receiving routine clinical care at 46 movement disorder centers in the United States and Canada.
Main Outcome Measures: The Massachusetts Gambling Screen score for current problem/pathological gambling, the Minnesota Impulsive Disorders Interview score for compulsive sexual behavior and buying, and Diagnostic and Statistical Manual of Mental Disorders research criteria for binge-eating disorder.
Results: An ICD was identified in 13.6% of patients (gambling in 5.0%, compulsive sexual behavior in 3.5%, compulsive buying in 5.7%, and binge-eating disorder in 4.3%), and 3.9% had 2 or more ICDs. Impulse control disorders were more common in patients treated with a dopamine agonist than in patients not taking a dopamine agonist (17.1% vs 6.9%; odds ratio [OR], 2.72; 95% confidence interval [CI], 2.08-3.54; P < .001). Impulse control disorder frequency was similar for pramipexole and ropinirole (17.7% vs 15.5%; OR, 1.22; 95% CI, 0.94-1.57; P = .14). Additional variables independently associated with ICDs were levodopa use, living in the United States, younger age, being unmarried, current cigarette smoking, and a family history of gambling problems.
Conclusions: Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD. This association represents a drug class relationship across ICDs. The association of other demographic and clinical variables with ICDs suggests a complex relationship that requires additional investigation to optimize prevention and treatment strategies.
Trial Registration: clinicaltrials.gov Identifier: NCT00617019.
Culicetto L, Impellizzeri F, Lo Buono V, Marafioti G, Di Lorenzo G, Sorbera C J Clin Med. 2025; 14(3).
PMID: 39941408 PMC: 11818531. DOI: 10.3390/jcm14030737.
Peng Z, Jia Q, Mao J, Luo X, Huang A, Zheng H Front Psychiatry. 2025; 15:1439727.
PMID: 39876994 PMC: 11773674. DOI: 10.3389/fpsyt.2024.1439727.
Staubo S, Fuskevag O, Toft M, Lie I, Alvik K, Jostad P J Neurol. 2025; 272(2):134.
PMID: 39812843 PMC: 11735512. DOI: 10.1007/s00415-024-12870-8.
Impulse control disorders in Parkinson's disease: What's new?.
Marques A, Lewis S J Neurol. 2025; 272(2):138.
PMID: 39812828 DOI: 10.1007/s00415-024-12865-5.
Neuropsychiatric symptoms in Parkinson's disease: review of data from the Arab world.
Chabbouh A, Khalil H, Abboud C, Sader A, Khoury R J Int Med Res. 2024; 52(12):3000605241304646.
PMID: 39687936 PMC: 11653321. DOI: 10.1177/03000605241304646.